FDA Panel To Assess Excessive Sedation Linked To Lilly’s Zyprexa Depot Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Psychopharmacologic Drugs Advisory Committee will vote Feb. 6 on the safety and efficacy of the long-acting atypical antipsychotic.
You may also be interested in...
FDA Panel Gives Nod To Long-Acting Form Of Lilly’s Schizophrenia Drug Zyprexa
With appropriate label warnings, the excessive sedation side effect should not preclude approval of the atypical antipsychotic’s depot formulation.
FDA Panel Gives Nod To Long-Acting Form Of Lilly’s Schizophrenia Drug Zyprexa
With appropriate label warnings, the excessive sedation side effect should not preclude approval of the atypical antipsychotic’s depot formulation.
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.